Claudin 6: A target opportunity to develop effector-enhanced drug modalities

It provides prescription drug coverage for medicare part b and for people 65 years and older and those under age 21. It's up to the lab to interpret the results Venâncio Aires gabapentin for sale of these tests to confirm what you've taken. It is used topically and as an intramuscular injection, and can also be taken by mouth.

May be more efficacious and better tolerated than methotrexate 5 mg day-week in the treatment of active rheumatoid arthritis. In the us, the fda doesn’t regulate the production, sale, or viagra probepackung use of drugs, devices, or supplements. This is what you would call a “double edge sword.” the good news of all the positive reviews it gets is that it is a good product if you use it right and use and the bad news is that it is not a good product if you don’t.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 50
Format: PDF
Product Line: Brief Report
Product Code: LMBR0016
Release Date: May of 2022

Claudin 6 (CLDN6) is a compelling tumor antigen. The tetraspan membrane protein is a member of the claudin family of tight junction proteins. CLDN6 is an oncofetal tight junction molecule that is expressed during embryonic and fetal development, transcriptionally silenced in adult tissues, and re-expressed on the surface of several epithelial cancers. The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

Despite being an attractive target due to its exceptionally cancer cell selective expression, therapeutic monoclonal antibodies targeting CLDN6 are difficult to discover due to an abundance of closely related family members and an absolute need for high specificity. Many proteins in the claudin family have high sequence identity. Most similar to CLDN6 is CLDN9, and the two proteins differ at only three of 76 residues in their extracellular loops, creating a challenge for the development of highly selective CLDN6 antibodies.

This report describes and analyzes as of May 2022

  • The scientific rationale for CLDN6-targeted therapies based on target characteristics and its differential expression profile;
  • Preclinical proof-of-concept of CLDN6-targeted different drug modalities;
  • Clinical experience with CLDN6-targeted therapies;
  • Clinical indications suitable for development of CLDN6-targeted therapies and their patient populations;
  • The competitive landscape of CLDN6-targeted drug modalities in development;
  • Specific profiles of CLDN6-targeted drug modalities; and
  • Profiles of companies active in the development of anti-CLDN6 therapy candidates.

Effector-enhanced antibodies and cells such as antibody-drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific antibodies redirecting T-cells or specifically activating T-cells will be enabled by and benefit from the cancer selective expression profile and the high target selectivity to avoid on-target, off-tumor toxicity.

Despite the technical challenge, novel cellular and humoral CLDN6-targeted drug modalities have emerged and the first product candidates entered clinical development. The facts that preliminary clinical experience shows high anti-tumor activity of the first drug candidate and that the competitive field still is limited, make claudin 6 an exceptionally attractive target for drug discovery and development.

Table of Contents

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Experience with CLDN6-Targeted Drug Modalities

5          Clinical Indications & Patient Populations

6          Competitive Landscape & Drug Modalities

7          Drug & Cell Therapy Candidate Profiles

7.1       CAR T-Cells

7.2       Antibody-Drug Conjugates (ADC)

7.3       T-Cell Redirecting Bispecific Antibodies

7.4       T-Cell Activating Bispecific Antibodies

7.5       Failed Drug Modalities

8          Company Profiles   

9          References    

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01